HK1222387A1 - 作為 抑制劑的芳基吡咯並吡啶衍生的化合物 - Google Patents

作為 抑制劑的芳基吡咯並吡啶衍生的化合物

Info

Publication number
HK1222387A1
HK1222387A1 HK16110103.5A HK16110103A HK1222387A1 HK 1222387 A1 HK1222387 A1 HK 1222387A1 HK 16110103 A HK16110103 A HK 16110103A HK 1222387 A1 HK1222387 A1 HK 1222387A1
Authority
HK
Hong Kong
Prior art keywords
lrrk2
arylpyrrolopyridine
inhibitors
derived compounds
derived
Prior art date
Application number
HK16110103.5A
Other languages
English (en)
Inventor
Timothy Bedford Simon
Chen I-Jen
Wang Yikang
Stewart WILLIAMSON Douglas
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of HK1222387A1 publication Critical patent/HK1222387A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
HK16110103.5A 2013-04-18 2016-08-24 作為 抑制劑的芳基吡咯並吡啶衍生的化合物 HK1222387A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201300231 2013-04-18
PCT/EP2014/057482 WO2014170248A1 (en) 2013-04-18 2014-04-14 Arylpyrrolopyridine derived compounds as lrrk2 inhibitors

Publications (1)

Publication Number Publication Date
HK1222387A1 true HK1222387A1 (zh) 2017-06-30

Family

ID=59093654

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110103.5A HK1222387A1 (zh) 2013-04-18 2016-08-24 作為 抑制劑的芳基吡咯並吡啶衍生的化合物

Country Status (9)

Country Link
US (3) US9499542B2 (zh)
EP (1) EP2986608B1 (zh)
JP (1) JP6461097B2 (zh)
CN (1) CN105263930B (zh)
AR (1) AR095885A1 (zh)
ES (1) ES2642204T3 (zh)
HK (1) HK1222387A1 (zh)
TW (1) TW201533043A (zh)
WO (1) WO2014170248A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
IL299415A (en) 2016-06-16 2023-02-01 Denali Therapeutics Inc Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) * 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
WO2018155947A1 (ko) 2017-02-24 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
EP3604304B1 (en) * 2017-03-23 2022-09-07 Daegu-Gyeongbuk Medical Innovation Foundation Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
KR20190043437A (ko) * 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CN111433208B (zh) * 2017-12-05 2023-06-30 奥斯考泰克公司 作为lrrk2抑制剂的吡咯并(吡唑并)嘧啶衍生物
HRP20211784T1 (hr) 2017-12-14 2022-02-18 H. Lundbeck A/S Kombinacijski tretmani koji se sastoje od primjene 1h-pirazolo[4,3-b]piridina
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
JP7194738B2 (ja) 2017-12-20 2022-12-22 ハー・ルンドベック・アクチエゼルスカベット ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン
TW202012410A (zh) * 2018-07-23 2020-04-01 美國商拜爾布拉克斯股份有限公司 激酶拮抗劑及其製備和使用方法
KR101990739B1 (ko) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR101992059B1 (ko) * 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR102133595B1 (ko) * 2019-05-31 2020-07-13 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR20230091150A (ko) * 2020-10-29 2023-06-22 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도
CN112852954A (zh) * 2021-03-16 2021-05-28 江苏贝格尔生物医药有限公司 一种检测lrrk2基因1628多态性的引物和探针及试剂盒
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023239727A1 (en) * 2022-06-06 2023-12-14 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Lats inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612086B2 (en) * 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
WO2007076423A2 (en) 2005-12-22 2007-07-05 Smithkline Beecham Corporation INHIBITORS OF Akt ACTIVITY
CA2635899A1 (en) * 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
JP2009525350A (ja) * 2006-02-01 2009-07-09 スミスクライン ビーチャム コーポレーション Ｒａｆキナーゼ阻害薬として有用なピロロ［２，３，ｂ］ピリジン誘導体
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
WO2008110508A1 (en) * 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity
EA019103B1 (ru) * 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
PE20120506A1 (es) * 2009-03-19 2012-05-14 Medical Res Council Technology Derivados de pirazolopiridina como inhibidores de quinasas
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
GB201015949D0 (en) * 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
BR112013025761A2 (pt) * 2011-04-05 2018-05-29 Sloan Kettering Inst Cancer Res inibidores de hsp90
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物

Also Published As

Publication number Publication date
US9675594B2 (en) 2017-06-13
US9499542B2 (en) 2016-11-22
US20160102089A1 (en) 2016-04-14
AR095885A1 (es) 2015-11-18
US20140315901A1 (en) 2014-10-23
JP2016516791A (ja) 2016-06-09
EP2986608A1 (en) 2016-02-24
TW201533043A (zh) 2015-09-01
EP2986608B1 (en) 2017-08-23
US20170020850A1 (en) 2017-01-26
CN105263930A (zh) 2016-01-20
WO2014170248A1 (en) 2014-10-23
CN105263930B (zh) 2017-06-09
JP6461097B2 (ja) 2019-01-30
ES2642204T3 (es) 2017-11-15

Similar Documents

Publication Publication Date Title
HK1222387A1 (zh) 作為 抑制劑的芳基吡咯並吡啶衍生的化合物
HK1256999A1 (zh) Syk抑制劑
IL243578A0 (en) syk inhibitors
HK1210775A1 (zh) 作為激酶抑制劑的咪唑並三嗪甲腈
HK1208442A1 (zh) 作為 激酶抑制劑的取代的吡咯並嘧啶基氨基－苯並噻唑酮
EP2948450A4 (en) METALLOENZYMINHIBITORVERBINDUNGEN
HK1211578A1 (zh) 作為 激酶抑制劑的酰氨基咪唑並噠嗪
HK1216531A1 (zh) 新的抑制劑
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
GB201317609D0 (en) Inhibitor compounds
HK1222848A1 (zh) 用作 抑制劑的吡咯並三嗪
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
IL246230A0 (en) Amines thf quinazoline as pde1 inhibitors
HK1217481A1 (zh) 作為 抑制劑的氨基吡啶衍生的化合物
HK1217654A1 (zh) 作爲激酶抑制劑的呋喃酮化合物
GB201321328D0 (en) Inhibitor compounds